Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML-Reference-Cited by-同舟云学术

Evaluation of allogeneic hematopoietic SCT in younger adults with adverse karyotype AML

Published:2012-03-19 Issue:11 Volume:47 Page:1436-1441
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Hospital M A,Thomas X,Castaigne S,Raffoux E,Pautas C,Gardin C,Bourhis J-H,Reman O,de Revel T,Terré C,Preudhomme C,Fenaux P,Michallet M,Socié G,Dombret H

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt201249.pdf

Reference20 articles.

1. Burnett AK, Wheatley K, Goldstone AH, Stevens RF, Hann IM, Rees JH et al. The value of allogeneic bone marrow transplantation in patients with acute myeloid leukaemia at differing risk of relapse: results of the UK MRC AML 10 trial. Br J Haematol 2002; 118: 385–400.

2. Suciu S, Mandelli F, de Witte T, Zittoun R, Gallo E, Labar B et al. Allogeneic compared with autologous stem cell transplantation in the treatment of patients younger than 46 years with acute myeloid leukemia (AML) in first complete remission (CR1): an intention-to-treat analysis of the EORTC-GIMEMA AML-10 trial. Blood 2003; 102: 1232–1240.

3. Jourdan E, Boiron JM, Dastugue N, Vey N, Marit G, Rigal-Huguet F et al. Early allogeneic stem-cell transplantation for young adults with acute myeloid leukemia in first complete remission: an intent-to-treat long-term analysis of the BGMT expérience. J Clin Oncol 2005; 23: 7676–7684.

4. Burnett AK, Wheatley K, Goldstone AH, Stevens R, Hann I, Hills RK . Long-term results of the MRC AML10 trial. Clin Adv Hematol Oncol 2006; 4: 445–451.

5. Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM et al. Results of a HOVON/SAKK donor versus no-donor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007; 109: 3658–3666.

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. What Influences the Decision to Proceed to Transplant for Patients With AML in First Remission?;Journal of Clinical Oncology;2023-10-10

2. AlloHSCT for inv(3)(q21;q26)/t(3;3)(q21;q26) AML: a report from the acute leukemia working party of the European society for blood and marrow transplantation;Bone Marrow Transplantation;2018-04-18

3. Outcomes of allogeneic stem cell transplantation among patients with acute myeloid leukemia presenting active disease: Experience of a single European Comprehensive Cancer Center;Revista da Associação Médica Brasileira;2016-10

4. Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis;The Lancet Haematology;2015-10

5. Assessing the efficacy of allogeneic hematopoietic stem cells transplantation (allo-HSCT) by analyzing survival end points in defined groups of acute myeloid leukemia patients: A retrospective, multicenter Polish Adult Leukemia Group study;American Journal of Hematology;2015-09-21